secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001558370-23-014716
Event type: leadership
Sentiment:  neutral
Materiality: 0.90
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroBo Pharmaceuticals appoints Hyung Heon Kim as Chief Executive Officer and President
--------------------------------------------------------------------------------

- Hyung Heon Kim appointed CEO, President, and Principal Financial Officer effective August 11, 2023, succeeding interim CEO Joseph Hooker.
- Kim previously served as General Counsel and Senior Vice President of Dong-A ST, which holds approximately 60% of NeuroBo's common stock.
- Kim received an employment agreement with a $450,000 base salary, 50% target bonus, and a restricted stock unit award of 625,064 shares.
- Joseph Hooker's departure as interim CEO was unrelated to any disagreement with the company on operations or policies.
- Board committee changes include appointments of Mark A. Glickman, Na Yeon Kim, D. Gordon Strickland, and Andrew I. Koven to various committees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000155837023014716/0001558370-23-014716-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000155837023014716/nrbo-20230810x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-014716

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer